Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

SMR Women’s Health Meeting
June 17, 2025
We’re excited to share that Janette Robertson (Business Development Manager) and Professor Mo Alavijeh (Managing Director) will attend the SMR Women’s Health Meeting at Friends House, London. They look forward to meeting attendees and discussing collaboration opportunities in drug discovery and development, especially in women’s health. πŸ“… More info: https://www.smr.org.uk/Meetings/20250617/ 🀝 Let’s connect in London!
June 16, 2025
πŸ‘‰ www.pharmidex.com/medical-device-testing-services With over 23 years of experience in preclinical R&D, we’re expanding our capabilities to support the development and regulatory testing of innovative medical devices from biocompatibility assessments to in vitro and in vivo efficacy models. This new service allows us to collaborate even more closely with biotech companies, CRO partners, academic innovators and medical device startups helping bring safe, effective and transformative technologies to patients faster. Whether you're exploring a novel implant, delivery system, or diagnostic platform, our team is ready to support you at every step with the same scientific integrity and agility that Pharmidex is known for. πŸ’‘ Let’s accelerate innovation, together.
June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
More Posts